| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Eric Vittinghoff | Q37323613 |
| P2093 | author name string | Mary S Beattie | |
| Feng Lin | |||
| Beth Crawford | |||
| John Ziegler | |||
| P2860 | cites work | Clinical practice. Management of an inherited predisposition to breast cancer | Q36877519 |
| Incidence of second primary breast cancer among women with a first primary in Manitoba, Canada | Q38492314 | ||
| Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations. | Q43424801 | ||
| Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. | Q43800820 | ||
| Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis | Q43993876 | ||
| Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation | Q44317248 | ||
| Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. | Q46016693 | ||
| Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group | Q47189470 | ||
| Women's attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another: differences among English, French, and Canadian women | Q47609286 | ||
| Acceptance of preventive surgeries by Israeli women who had undergone BRCA testing. | Q52016846 | ||
| One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery). | Q52375755 | ||
| Insurance reimbursement for risk-reducing mastectomy and oophorectomy in women with BRCA1 or BRCA2 mutations. | Q54581835 | ||
| Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing | Q73210569 | ||
| Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing | Q74008289 | ||
| Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing | Q79214311 | ||
| STUDENTJAMA. Preparing for personalized medicine | Q79885742 | ||
| Recruitment, genetic counseling, and BRCA testing for underserved women at a public hospital | Q82091502 | ||
| Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies | Q24531993 | ||
| A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1 | Q28115843 | ||
| Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 | Q28212276 | ||
| Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium | Q29619206 | ||
| A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study | Q30431721 | ||
| Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. | Q34074423 | ||
| International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers | Q34116505 | ||
| Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation | Q34129784 | ||
| Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations | Q34129787 | ||
| Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. | Q34334383 | ||
| Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer | Q34417238 | ||
| Limited family structure and BRCA gene mutation status in single cases of breast cancer | Q34639377 | ||
| Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium | Q34724404 | ||
| Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation | Q35167622 | ||
| Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families | Q35238493 | ||
| Utilization of screening and preventive surgery among unaffected carriers of a BRCA1 or BRCA2 gene mutation | Q35983873 | ||
| Ovarian carcinoma screening in women at intermediate risk: impact on quality of life and need for invasive follow-up | Q36158193 | ||
| Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force | Q36250215 | ||
| Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a systematic review | Q36807594 | ||
| P433 | issue | 1 | |
| P1104 | number of pages | 6 | |
| P304 | page(s) | 51-56 | |
| P577 | publication date | 2009-02-01 | |
| P1433 | published in | Genetic Testing and Molecular Biomarkers | Q15753742 |
| P1476 | title | Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers | |
| P478 | volume | 13 |
| Q44400604 | Anticipatory loss and early mastectomy for young female BRCA1/2 mutation carriers |
| Q41195564 | Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction |
| Q48629272 | Cancer risk management in Tasmanian women with BRCA1 and BRCA2 mutations |
| Q59809876 | Cell Origins of High-Grade Serous Ovarian Cancer |
| Q35687632 | Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review |
| Q38213995 | Comparison of risk management strategies between women testing positive for a BRCA variant of unknown significance and women with known BRCA deleterious mutations |
| Q57216406 | Different Patterns of Risk Reducing Decisions in Affected or Unaffected BRCA Pathogenic Variant Carriers |
| Q34125241 | Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers? |
| Q46971163 | Factors affecting the decision to undergo risk-reducing salpingo-oophorectomy among women with BRCA gene mutation. |
| Q44696764 | Factors influencing uptake and timing of risk reducing salpingo-oophorectomy in women at risk of familial ovarian cancer: a competing risk time to event analysis |
| Q51599191 | Female BRCA mutation carriers with a preference for prophylactic mastectomy are more likely to participate an educational-support group and to proceed with the preferred intervention within 2 years. |
| Q51017508 | Follow-up of carriers of BRCA1 and BRCA2 variants of unknown significance: variant reclassification and surgical decisions. |
| Q89578180 | Healthcare Utilization and Costs after Receiving a Positive BRCA1/2 Result from a Genomic Screening Program |
| Q38684207 | Heightened perception of breast cancer risk in young women at risk of familial breast cancer |
| Q35777905 | Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance |
| Q35815469 | Long-term psychosocial outcomes of BRCA1/BRCA2 testing: differences across affected status and risk-reducing surgery choice |
| Q37688802 | Long-term satisfaction and quality of life following risk reducing surgery in BRCA1/2 mutation carriers |
| Q36925172 | Management of the asymptomatic BRCA mutation carrier |
| Q37991240 | Managing the breast in patients who test positive for hereditary breast cancer |
| Q35021170 | New Strategies in Ovarian Cancer: Uptake and Experience of Women at High Risk of Ovarian Cancer Who Are Considering Risk-Reducing Salpingo-Oophorectomy |
| Q35617340 | Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment |
| Q38759417 | Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors |
| Q44657438 | Rates of risk-reducing surgery in Israeli BRCA1 and BRCA2 mutation carriers |
| Q44723118 | Risk management options elected by women after testing positive for a BRCA mutation. |
| Q39064164 | Risk-reducing salpingectomy with delayed oophorectomy in BRCA1/2 mutation carriers: patients' and professionals' perspectives |
| Q37185670 | Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing |
| Q36457900 | Role of Breast Surgery in BRCA Mutation Carriers |
| Q41035840 | Study on the psychosocial aspects of risk-reducing salpingo-oophorectomy (RRSO) in BRCA1/2 mutation carriers in Japan: a preliminary report |
| Q38676694 | Surgical Decision Making in the BRCA-Positive Population: Institutional Experience and Comparison with Recent Literature |
| Q84004623 | Surveillance of survivors: follow-up after risk-reducing salpingo-oophorectomy in BRCA 1/2 mutation carriers |
| Q36240959 | The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy |
| Q38905495 | The effect of referral for genetic counseling on genetic testing and surgical prevention in women at high risk for ovarian cancer: Results from a randomized controlled trial |
| Q34481713 | The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: Implications for counseling |
| Q30896495 | Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON study |
| Q38599703 | Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea |
| Q34475484 | Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers |
| Q38840468 | Very high uptake of risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers: A single-center experience. |
Search more.